TY - JOUR
T1 - Targeting base excision repair for chemosensitization
AU - Adhikari, Sanjay
AU - Choudhury, Sujata
AU - Mitra, Partha S.
AU - Dubash, Jerita J.
AU - Sajankila, Shyama P.
AU - Roy, Rabindra
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/5
Y1 - 2008/5
N2 - In both bacteria and eukaryotes the alkylated, oxidized, and deaminated bases and depurinated lesions are primarily repaired via an endogenous preventve pathway, i.e. base excision repair (BER). Radiation therapy and chemotherapy are two important modes of cancer treatment Many of those therapeutic agents used in the clinic have the ability to induce the DNA damage; however, they may also be highly cytotoxic, causing peripheral toxicity and secondary cancer as adverse side effects. In addition, the damage produced by the therapeutic agents can often be repaired by the BER proteins, which in effect confers therapeutic resistance. Efficient inhibition of a particular BER protein(s) may increase the efficacy of current chemotherapeutic regimes, which minimizes resistance and ultimately decreases the possibility of the aforementioned negative side effects. Therefore, pharmacological inhibition of DNA damage repair pathways may be explored as a useful strategy to enhance chemosensitivity. Various agents have shown excellent results in preclinical studies in combination chemotherapy. Early phase clinical trials are now being carried out using DNA repair inhibitors targeting enzymes such as PARP, DNA-PK or MGMT. In the case of BER proteins, elimination of N-Methylpurine DNA glycosylase (MPG) or inhibition of P-endonuclease (APE) increased sensitivity of cancer cells to alkylating chemotherapeutics. MPG-/- embryonic stem cells and cells having MPG knock-down by siRNA are hypersensitive to alkylating agents, whereas inhibition of APE by small molecule inhibitors sensitized cancer cells to alkylating chemotherapeutics. Thus, MPG and other BER proteins could be potential targets for chemosensitization.
AB - In both bacteria and eukaryotes the alkylated, oxidized, and deaminated bases and depurinated lesions are primarily repaired via an endogenous preventve pathway, i.e. base excision repair (BER). Radiation therapy and chemotherapy are two important modes of cancer treatment Many of those therapeutic agents used in the clinic have the ability to induce the DNA damage; however, they may also be highly cytotoxic, causing peripheral toxicity and secondary cancer as adverse side effects. In addition, the damage produced by the therapeutic agents can often be repaired by the BER proteins, which in effect confers therapeutic resistance. Efficient inhibition of a particular BER protein(s) may increase the efficacy of current chemotherapeutic regimes, which minimizes resistance and ultimately decreases the possibility of the aforementioned negative side effects. Therefore, pharmacological inhibition of DNA damage repair pathways may be explored as a useful strategy to enhance chemosensitivity. Various agents have shown excellent results in preclinical studies in combination chemotherapy. Early phase clinical trials are now being carried out using DNA repair inhibitors targeting enzymes such as PARP, DNA-PK or MGMT. In the case of BER proteins, elimination of N-Methylpurine DNA glycosylase (MPG) or inhibition of P-endonuclease (APE) increased sensitivity of cancer cells to alkylating chemotherapeutics. MPG-/- embryonic stem cells and cells having MPG knock-down by siRNA are hypersensitive to alkylating agents, whereas inhibition of APE by small molecule inhibitors sensitized cancer cells to alkylating chemotherapeutics. Thus, MPG and other BER proteins could be potential targets for chemosensitization.
KW - AP-endonuclease
KW - Base excision repair
KW - Chemoresistance
KW - DNA repair
KW - Drug targets
KW - Methoxyamine
KW - Methyl methane sulfonate
KW - N-methylpurine DNA-glycosylase
KW - O-methylguanine methyl transferase
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=44449097296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44449097296&partnerID=8YFLogxK
U2 - 10.2174/187152008784220366
DO - 10.2174/187152008784220366
M3 - Article
C2 - 18473720
AN - SCOPUS:44449097296
SN - 1871-5206
VL - 8
SP - 351
EP - 357
JO - Anti-Cancer Agents in Medicinal Chemistry
JF - Anti-Cancer Agents in Medicinal Chemistry
IS - 4
ER -